Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures sink as AI doubts resurface, oil jumps
- Oil jumps on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
| Actinium Pharmaceuticals, Inc. (NYSE: ATNM) | Delayed: 1.38 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.38 | 52 Week High | $3.50 | |||
| Open | $1.38 | 52 Week Low | $0.86 | |||
| Day High | $1.38 | P/E | N/A | |||
| Day Low | $1.38 | EPS | $-7.61 | |||
| Volume | 11,716 | |||||
